Primary Care

Lipid Disorders

Questions discussed in this category

Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?

Ferrell et al., PMID 38448791

6 Answers available

How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?

1 Answer available

Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?

4 Answers available

Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?

1 Answer available

Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?

1 Answer available

Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?

At what doses do you start? and how do you titrate therapy?

1 Answer available

Do you recommend the use of bempedoic acid (Nexletol) for treatment of hyperlipidemia in patients with elevated baseline uric acid levels?

Should uric acid levels be monitored regularly while on therapy?

1 Answer available

Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?

Cholesterol Treatment Trialists' (CTT) Collaboration

2 Answers available

For patients with metabolic syndrome, is it reasonable to wait for the effect of tirzepatide therapy on their lipid profile prior to starting statin therapy?

4 Answers available

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

1 Answer available

Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?

3 Answers available

When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?

3 Answers available

How do you counsel patients with non-statin associated inflammatory myopathies about statin use?

1 Answer available

Should Orlistat be considered in the management of hypertriglyceridemia?

1 Answer available

Would you treat an isolated elevated total cholesterol in a post-menopausal patient who is otherwise healthy and has no significant CV risk factors?

2 Answers available

Should patients with mild subclinical hypothyroidism (TSH < 10 mIU/L) be treated with thyroid hormone replacement to improve their lipid profile?

2 Answers available

Should lipid lowering therapy be started in patients with isolated elevation in lipoprotein (a) and minimal cardiovascular risk?

2 Answers available

Should insulin be started early (prior to optimization of other anti-hyperglycemic medications) in patients with mild-to-moderate diabetes and hypertriglyceridemia refractory to statin and fibrates?

2 Answers available

Papers discussed in this category

Journal of the American Heart Association, 2015 Jun 26

Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Mayo Clinic proceedings, 2023 Jun 29

Progression to Insulin Therapy in Patients With Type 2 Diabetes According to Cardiorespiratory Fitness, Body Mass Index, and Statin Therapy.

The Journal of clinical endocrinology and metabolism, 2011 Dec 28

Update in lipid alterations in subclinical hypothyroidism.

Curr Rheumatol Rep, 2020 Aug 26

Lipid-lowering Therapies in Myositis.

The American journal of cardiology, 2004-02-01

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

Nature medicine, 2024 Feb 19

A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.

Journal of clinical lipidology, 2024 Mar 29

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.

Journal of the American College of Cardiology, 1986-12

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

The New England journal of medicine, 2011-12-15

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Current opinion in lipidology, 2007 Aug

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

The American journal of cardiology, 2005 Jun 01

Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.

Trials, 2018 Mar 05

Improved adherence adjustment in the Coronary Drug Project.

The New England journal of medicine, 2014 Jul 17

Effects of extended-release niacin with laropiprant in high-risk patients.

JAMA, 1975 Jan 27

Clofibrate and niacin in coronary heart disease.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

Circulation, 2019-06-18

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Journal of clinical lipidology, 2022 Sep 11

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.

Primary Care

Lipid Disorders

Questions discussed in this category

Papers discussed in this category

Related Topics in Primary Care